Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : ARX305 is the only anti-CD70 ADC in active development that targets CD70, a protein that is overexpressed in a broad range of solid and hematologic tumors, giving it the potential to treat a range of liquid and solid tumor cancers, where CD70 is overexpr...
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
September 11, 2022
Lead Product(s) : ARX788
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Recipient : Ambrx Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Patients who failed prior Kadcyla® (T-DM1) or Enhertu® (DS-8201a) achieved clinical responses, as assessed by RECIST v1.1 in the ACE-Pan Tumor-01 (ARX788-1711) tria.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
October 12, 2020
Lead Product(s) : ARX788
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : Ambrx Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vitamin E
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : R&G PharmaStudies Co | The Affiliated Hospital of Hangzhou Normal University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
November 11, 2016
Lead Product(s) : Vitamin E
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : R&G PharmaStudies Co | The Affiliated Hospital of Hangzhou Normal University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemonoxacin
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 21, 2016
Lead Product(s) : Nemonoxacin
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemonoxacin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Huashan Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 13, 2015
Lead Product(s) : Nemonoxacin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Huashan Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 30, 2015
Reset All
